Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC lowered its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 43.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,952 shares of the company’s stock after selling 3,059 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Viridian Therapeutics were worth $76,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Nebula Research & Development LLC acquired a new position in shares of Viridian Therapeutics in the 4th quarter valued at $328,000. Lord Abbett & CO. LLC boosted its holdings in shares of Viridian Therapeutics by 17.3% in the 4th quarter. Lord Abbett & CO. LLC now owns 459,588 shares of the company’s stock valued at $8,810,000 after purchasing an additional 67,630 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Viridian Therapeutics by 5.1% in the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock valued at $410,000 after purchasing an additional 1,038 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Viridian Therapeutics by 38.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,670,000 shares of the company’s stock valued at $32,014,000 after purchasing an additional 465,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Viridian Therapeutics by 2,847.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company’s stock valued at $25,436,000 after purchasing an additional 1,281,799 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have weighed in on VRDN. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Viridian Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $13.53 on Tuesday. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a market cap of $1.10 billion, a PE ratio of -3.14 and a beta of 0.81. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company’s fifty day simple moving average is $14.18 and its 200-day simple moving average is $18.14.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.